

Supplementary Materials

Repurposing of the anti-HIV drug Emtricitabine as a hydrogen-bonded cleft for bipyridines via cocrystallization

Gonzalo Campillo-Alvarado, Elizabeth A. Keene, Dale C. Swenson and Leonard R. MacGillivray*

Department of Chemistry, University of Iowa, Iowa City, IA, 52242-1294, USA.
e-mail: len-macgillivray@uiowa.edu

Supplementary Information:

S1. Materials and Instrumentation

S2. Single Crystal X-Ray Diffraction Data

S3. Powder X-Ray Diffraction Data

S4. ^1H NMR Data

S5. Attenuated Total Reflection Fourier Transform IR Spectroscopy Data

S1. Materials and Instrumentation

S1.1. Materials

Emtricitabine (**FTC**) was purchased from Combi-Blocks Inc., 1,2-Bis(4-pyridyl)ethane (**bpeta**), 1,2-bis(4-pyridyl)ethylene (**bpe**), 4-azopyridine (**apy**) and 4,4'-bipyridine (**bipy**) and solvents were purchased from Sigma Aldrich. All reagents and solvents were used without further purification.

Cocrystals (**FTC**)₂·(**bpeta**), (**FTC**)₂·(**bpe**) and (**FTC**)₂·(**apy**) were obtained by combining **FTC** (40 mg, 0.162 mmol) with the corresponding bipyridine (0.081 mmol) through liquid-assisted grinding (LAG, methanol)¹ for 15 min. The resulting solids were dissolved in warm methanol (2 mL). Slow evaporation of the solution (2-3 days) afforded single crystals suitable for X-ray diffraction.

Cocrystal (**FTC**)₂·(**bipy**)₂·H₂O were obtained by combining **FTC** (40 mg, 0.162 mmol) with 4,4'-bipyridyl (25.3 mg, 0.162 mmol) through liquid-assisted grinding (LAG, methanol)¹ for 15 min. The resulting solids were dissolved in warm methanol (2 mL). Slow evaporation of the solution (2-3 days) afforded single crystals suitable for X-ray diffraction.

Instrumentation

Single crystal X-ray diffraction data were collected on a Bruker D-8 Venture diffractometer equipped with a Duo-Photon 3 area detector using Mo-K α radiation ($\lambda_{\text{MoK}\alpha}$ = 0.71073 Å, diffraction source: Incoatec micro-source 3.0 Mo). The frames were integrated with the Bruker SAINT software package using a narrow-frame algorithm. Data were corrected for absorption effects using the Multi-Scan method (SADABS). Structure solution, refinement and data output were carried out with Olex2 software package² using XT, VERSION 2014/5 (solution using direct methods)³ and XL, VERSION 2018/3 (refinement using full-matrix least-squares on F^2).⁴ Non-hydrogen atoms were refined anisotropically and hydrogen atoms were placed in geometrically calculated positions using a riding model. Crystal structures were generated using Mercury.

Powder X-ray diffraction data were collected from samples mounted on a glass slide by a Bruker D8 Avance X-ray diffractometer using $\text{CuK}\alpha_1$ radiation ($\lambda = 1.5418 \text{ \AA}$) typically in the range of $2\theta = 5\text{--}35^\circ$ (scan mode: continuous PSD fast; step size: 0.019°). The equipment was operated at 40 kV and 30 mA, and data were acquired at room temperature.

IR spectra have been recorded on a Thermo Scientific Nicolet 380 FT-IR spectrometer and measured in the range of $3600\text{--}750 \text{ cm}^{-1}$ equipped with a diamond ATR crystal.

^1H NMR spectra were recorded using a Bruker AVANCE 300 NMR spectrometer operating at 300 MHz using $\text{DMSO-}d_6$ as solvent. Signal assignment for **FTC** was based on previous reports.⁵ All data were processed with Mnova suite.

Methods

Force field intermolecular energy calculations were carried out using the UNI intermolecular potentials algorithm in CSD-Materials from the CCDC software package using the CIF files generated from single crystal X-ray diffraction refinement. Intermolecular energies within cocrystals were calculated for the highest-contributing intermolecular interactions.⁶

S2. Single-crystal X-ray diffraction data

Table S1. Crystallographic parameters for (FTC)₂·(bpeta), (FTC)₂·(bpe), (FTC)₂·(apy) and (FTC)₂·(bipy)₂·H₂O

Compound name	(FTC) ₂ ·(bpeta)	(FTC) ₂ ·(bpe)	(FTC) ₂ ·(apy)	(FTC) ₂ ·(bipy) ₂ ·H ₂ O
Empirical formula	(C ₈ H ₁₀ FN ₃ O ₃ S) ₂ ·(C ₁₂ H ₁₂ N ₂)	(C ₈ H ₁₀ FN ₃ O ₃ S) ₂ ·(C ₁₂ H ₁₀ N ₂)	(C ₈ H ₁₀ FN ₃ O ₃ S) ₂ ·(C ₁₂ H ₈ N ₄)	(C ₈ H ₁₀ FN ₃ O ₃ S) ₂ ·(C ₁₀ H ₈ N ₂) ₂ ·H ₂ O
Formula weight	678.73	676.72	677.69	824.895
Temperature/K	296.15	298.15	296.15	150.15
Crystal system	monoclinic	monoclinic	monoclinic	monoclinic
Space group	<i>P</i> 2 ₁	<i>P</i> 2 ₁	<i>P</i> 2 ₁	<i>P</i> 2 ₁
<i>a</i> /Å	7.6333(8)	7.4883(7)	7.5024(8)	7.4668(10)
<i>b</i> /Å	11.2359(11)	11.2957(11)	11.2194(11)	9.6700(14)
<i>c</i> /Å	18.1058(18)	18.1735(18)	18.2134(18)	26.187(4)
α /°	90	90	90	90
β /°	99.640(5)	100.406(5)	100.538(5)	90.087(4)
γ /°	90	90	90	90
Volume/Å ³	1531.0(3)	1511.9(3)	1507.2(3)	1890.8(5)
<i>Z</i>	2	2	2	2
ρ_{calc} /cm ³	1.472	1.486	1.493	1.449
μ /mm ⁻¹	0.243	0.246	0.249	0.215
<i>F</i> (000)	708.0	704.0	702.0	860.9
Crystal size/mm ³	0.185 × 0.055 × 0.05	0.145 × 0.065 × 0.03	0.13 × 0.095 × 0.02	0.115 × 0.1 × 0.06
Radiation	MoK α (λ = 0.71073)	MoK α (λ = 0.71073)	MoK α (λ = 0.71073)	Mo K α (λ = 0.71073)
2 θ range for data collection/°	5.512 to 49.994	5.532 to 56.542	4.55 to 55.786	4.5 to 52.98
Index ranges	-9 ≤ <i>h</i> ≤ 9, -13 ≤ <i>k</i> ≤ 13, -21 ≤ <i>l</i> ≤ 21	-9 ≤ <i>h</i> ≤ 9, -14 ≤ <i>k</i> ≤ 13, -24 ≤ <i>l</i> ≤ 17	-9 ≤ <i>h</i> ≤ 9, -14 ≤ <i>k</i> ≤ 14, -23 ≤ <i>l</i> ≤ 23	-9 ≤ <i>h</i> ≤ 9, -12 ≤ <i>k</i> ≤ 12, -32 ≤ <i>l</i> ≤ 32
Reflections collected	15295	12872	32670	48450
Independent reflections	5271 [<i>R</i> _{int} = 0.0313, <i>R</i> _{sigma} = 0.0339]	6094 [<i>R</i> _{int} = 0.0238, <i>R</i> _{sigma} = 0.0337]	7064 [<i>R</i> _{int} = 0.0428, <i>R</i> _{sigma} = 0.0350]	7767 [<i>R</i> _{int} = 0.0550, <i>R</i> _{sigma} = 0.0423]
Data/restraints/parameters	5271/1/446	6094/1/417	7064/6/424	7767/49/508
Goodness-of-fit on <i>F</i> ²	1.024	1.059	1.073	1.038
Final <i>R</i> indexes [<i>I</i> > 2 σ (<i>I</i>)]	<i>R</i> ₁ = 0.0292, <i>wR</i> ₂ = 0.0677	<i>R</i> ₁ = 0.0369, <i>wR</i> ₂ = 0.0838	<i>R</i> ₁ = 0.0487, <i>wR</i> ₂ = 0.1106	<i>R</i> ₁ = 0.0559, <i>wR</i> ₂ = 0.1267
Final <i>R</i> indexes [all data]	<i>R</i> ₁ = 0.0325, <i>wR</i> ₂ = 0.0700	<i>R</i> ₁ = 0.0427, <i>wR</i> ₂ = 0.0869	<i>R</i> ₁ = 0.0591, <i>wR</i> ₂ = 0.1157	<i>R</i> ₁ = 0.0633, <i>wR</i> ₂ = 0.1307
Largest diff. peak/hole / e Å ⁻³	0.14/-0.15	0.26/-0.19	0.48/-0.22	0.42/-0.39
CCDC deposition number	1981473	1981474	1981475	1981476

Table S2. Hydrogen bond and $\pi\cdots\pi$ contact parameters for **(FTC)₂·(bpeta)**, **(FTC)₂·(bpe)**, **(FTC)₂·(apy)** and **(FTC)₂·(bipy)₂·H₂O**.

Cocrystal	D–H...A/ Centroid...Centroid	d(D–H) [Å]	d(H...A) [Å]	d(D...A) [Å]	$\angle$ (D–H...A) [deg]	Symmetry code
(FTC)₂·(bpeta)	O1–H1...N7	0.817	2.024	2.838	174.11	-
	O4–H4A...N8	0.803	2.050	2.850	174.38	-
	N3–H3A...N5	0.867	2.126	2.989	173.93	-
	N6–H6A...N2	0.912	2.022	2.922	169.03	-
	N3–H3B...F1	0.867	2.482	2.766	99.83	-
	N6–H6B...F2	0.805	2.420	2.733	104.33	-
	C12–H12...F2	0.980	2.540	3.347	139.59	-x+2, y-1/2, -z
	C8–H8...O3	0.930	2.491	3.213	134.64	-x+2, y-1/2, -z+1
	C12–H12...F2	0.980	2.540	3.347	139.59	-x+2, y-1/2, -z
	C11–H11B...O6	0.970	2.472	3.291	141.93	-x+2, y+1/2, -z
	C3–H3C...N7	0.970	2.663	3.349	127.97	x+1, y, z
	C3–H3D...O3	0.970	2.461	3.417	168.47	-x+2, y-1/2, -z+1
	C28–H28...O6	0.930	2.592	3.342	137.95	-x+1, y+1/2, -z
	N3–H3B...O4	0.867	2.271	3.042	148.09	-x+1, y-1/2, -z
	N6–H6B...S1	0.805	2.759	3.516	157.35	-x+2, y+1/2, -z+1
	Cg1...Cg2 ^[a]	-	-	3.918	-	-
	Cg3...Cg4 ^[a]	-	-	3.682	-	-
(FTC)₂·(bpe)	O1–H1...N7	0.820	2.054	2.863	169.27	-
	O4–H4A...N8	0.820	2.044	2.858	171.24	-
	N6–H6A...N2	0.860	2.047	2.900	170.95	-
	N3–H3A...N5	0.860	2.108	2.965	174.03	-
	C16–H16...S2	0.930	3.007	3.621	124.94	-
	N3–H3B...F1	0.867	2.454	2.766	102.16	-
	N6–H6B...F2	0.860	2.412	2.735	102.85	-
	N6–H6B...S1	0.860	2.728	3.535	156.74	-x+2, y+1/2, -z+1
	N3–H3B...O4	0.860	2.774	3.024	145.74	-x+1, y-1/2, -z
	C8–H8...O3	0.930	2.455	3.174	134.22	-x+1, y-1/2, -z
	C16–H16...O6	0.930	2.630	3.322	131.65	-x+2, y+1/2, -z
	C12–H12...F2	0.980	2.495	3.299	139.17	-x+2, y-1/2, -z
	C3–H3C...N7	0.970	2.664	3.313	124.61	x+1, y, z
	C3–H3D...O3	0.970	2.470	3.428	169.35	-x+2, y-1/2, -z+1
	C18–H18...S2	0.930	3.019	3.877	154.09	-x+1, y-1/2, -z
	C11–H11B...O6	0.970	2.479	3.276	139.25	-x+2, y+1/2, -z
	C11–H11B...N8	0.970	2.680	3.348	126.37	x+1, y, z
	Cg1...Cg2 ^[b]	-	-	3.798	-	-

	Cg3...Cg4 ^[b]	-	-	3.666	-	-
(FTC) ₂ ·(apy)	O1–H1...N7	0.820	2.074	2.886	170.26	-
	O4–H4A...N8	0.820	2.079	2.894	172.32	-
	N3–H3A...N5	0.860	2.109	2.964	172.55	-
	C14–H14...S2	0.930	2.927	3.552	125.79	-
	N6–H6A...N2	0.860	2.055	2.908	171.06	-
	N3–H3B...F1	0.860	2.457	2.766	102.07	
	N6–H6B...F2	0.860	2.412	2.734	102.80	
	C8–H8...O3	0.930	2.492	3.214	134.55	-x, y-1/2, -z+1
	N3–H3B...O4	0.860	2.331	3.093	147.84	-x+1, y-1/2, -z+2
	C12–H12...F2	0.980	2.489	3.299	139.83	-x, y-1/2, -z+2
	C11–H11B...O6	0.970	2.451	3.251	139.51	-x, y+1/2, -z+2
	N6–H6B...S1	0.860	2.746	3.545	155.23	-x, y+1/2, -z+1
	C3–H3C...O1	0.970	2.556	3.289	132.44	x-1, y, z
	C3–H3D...O3	0.970	2.447	3.408	170.69	-x, y-1/2, -z+1
	C9–H9...S1	0.930	2.818	3.616	144.63	x+1, y, z+1
	C26–H26...S1	0.930	2.582	3.330	137.77	-x+1, y+1/2, -z+2
	C9–H9...S1	0.930	2.934	3.787	153.13	-x+1, y-1/2, -z+2
	Cg1...Cg2 ^[c]	-	-	3.755	-	-
	Cg3...Cg4 ^[c]	-	-	3.688	-	-
(FTC) ₂ ·(bipy) ₂ ·H ₂ O	O1–H1...N7	0.840	1.968	2.786	164	-
	O4–H4A...N9	0.840	2.106	2.836	145	-
	O7–H7A...N10	0.870	2.053	2.851	152	-
	O7–H7B...O1	0.870	2.023	2.855	160	-
	N3–H3B...F1	0.880	2.443	2.762	101.87	
	N6–H6B...F2	0.880	2.432	2.754	102.05	
	N3–H3B...O1	0.880	2.281	3.097	105	1+x, y, z
	N3–H3A...O6	0.880	2.344	3.210	168	x, y, z-1
	N3–H3A...N5	0.880	2.357	3.028	133	1+x, y, z
	C4–H4...F1	0.880	2.308	3.122	137	-1+x, y, z
	Cg1...Cg2 ^[d]	-	-	3.779	-	-
	Cg3...Cg4 ^[d]	-	-	3.724	-	-

^[a]Cg1 = N1, N2, C5–C8; Cg2 = N7, C17–C21; Cg3 = N4, N5, C13–C16; Cg4 = N8, C24–C28. ^[b]Cg1 = N1, N2, C5–C8; Cg2 = N7, C17–C21; Cg3 = N4, N5, C13–C16; Cg4 = N8, C24–C28. ^[c]Cg1 = N1, N2, C5–C8; Cg2 = N7, C17–C21; Cg3 = N4, N5, C13–C16; Cg4 = N8, C24–C28. ^[d]Cg1 = N7, C17–C21; Cg2 = N10, C27–C31; Cg3 = N8, C22–C26; Cg4 = N9, C32–C35.




Figure S1. X-ray structure of FTC: (a) homodimer sustained by N-H...N hydrogen bonds, (b) two-point synthon, and (c) 1D ribbon sustained by N-H...O hydrogen bonds (CSD refcode: HAKJIM).⁷




Figure S2. Intermolecular interaction energies (kJ mol⁻¹) and distances (Å) of highest-contributing interactions of crystal structures of (FTC)₂·(bpeta), (FTC)₂·(bpe), (FTC)₂·(apy) and (FTC)₂·(bipy)₂·H₂O.⁶




Table S3. Selected intermolecular interaction energies (kJ mol^{-1}) for $(\text{FTC})_2 \cdot (\text{bpeta})$, $(\text{FTC})_2 \cdot (\text{bpe})$ and $(\text{FTC})_2 \cdot (\text{apy})$.

Compound name / Intermolecular interaction energies of fragments (kJ mol^{-1}) ¹	$(\text{FTC})_2 \cdot (\text{bpeta})$	$(\text{FTC})_2 \cdot (\text{bpe})$	$(\text{FTC})_2 \cdot (\text{apy})$	$(\text{FTC})_2 \cdot (\text{bipy})_2 \cdot \text{H}_2\text{O}$
I-II	-57.8	-57.6	-55.7	-
I-III	-58.9	-58.4	-58.8	-
I-IV	-37.3	-38.6	-39.1	-
I-V	-37.0	-35.5	-34.9	-
II-III	-25.2	-24.1	-21.3	-
Total packing energy	-443.0	-441.8	-432.0	-555.6

¹Calculated based on the crystal structures containing highest occupancies in case of disorder.

S3. Powder X-ray diffraction (PXRD) data




Fig. S3. PXRD analysis of $(\text{FTC})_2 \cdot (\text{bpeta})$: (a) calculated powder pattern using single crystal X-ray data, (b) experimental powder pattern, (c) bpeta (experimental) and (d) FTC (experimental). Appearance of a new set of peaks in (a) and (b) compared to starting materials reflects the formation of a new solid phase.




Fig. S4. PXRD analysis of $(\text{FTC})_2 \cdot (\text{bpe})$: (a) calculated powder pattern using single crystal X-ray data, (b) experimental powder pattern, (c) bpe (experimental) and (d) FTC

(experimental). Appearance of a new set of peaks in **(a)** and **(b)** compared to starting materials reflects the formation of a new solid phase.




Fig. S5. PXRD analysis of **(FTC)₂·(apy)**: **(a)** calculated powder pattern using single crystal X-ray data, **(b)** experimental powder pattern, **(c) apy** (experimental) and **(d) FTC** (experimental). Appearance of a new set of peaks in **(a)** and **(b)** compared to starting materials reflects the formation of a new solid phase.





Fig. S6. PXRD analysis of **(FTC)₂·(bipy)₂·H₂O**: **(a)** calculated powder pattern using single crystal X-ray data, **(b)** experimental powder pattern, **(c) bipy** (experimental) and **(d) FTC**

(experimental). Appearance of a new set of peaks in **(a)** and **(b)** compared to starting materials reflects the formation of a new solid phase.



S4. ¹H NMR Data

Fig. S7. ¹H NMR spectra of **FTC** (300 MHz, DMSO-*d*₆, 16.18 mM, 26.85 °C).




Fig. S8. ¹H NMR spectra of **(FTC)₂·(bpeta)** (300 MHz, DMSO-*d*₆, 9.28 mM, 26.85 °C).




Fig. S9. ¹H NMR spectra of **(FTC)₂·(bpe)** (300 MHz, DMSO-*d*₆, 9.34 mM, 26.85 °C).




Fig. S10. ^1H NMR spectra of $(\text{FTC})_2 \cdot (\text{apy})$ (300 MHz, $\text{DMSO}-d_6$, 9.28 mM, 26.85 $^\circ\text{C}$).




Fig. S11. ^1H NMR spectra of $(\text{FTC})_2 \cdot (\text{bipy})_2 \cdot \text{H}_2\text{O}$ (300 MHz, $\text{DMSO}-d_6$, 14.16 mM, 26.85 $^\circ\text{C}$).

S5. Attenuated Total Reflection Fourier Transform IR Spectroscopy Data




Fig. S12. ATR-IR spectrum of (a) **bpeta**, (b) **FTC** and $(\text{FTC})_2 \cdot (\text{bpeta})$.




Fig. S13. ATR-IR spectrum of (a) **bpe**, (b) **FTC** and $(\text{FTC})_2 \cdot (\text{bpe})$.




Fig. S14. ATR-IR spectrum of (a) **apy**, (b) **FTC** and **(FTC)₂·(apy)**.




Fig. S15. ATR-IR spectrum of (a) **bipy**, (b) **FTC** and **(FTC)₂·(bipy)₂·H₂O**.

References

1. S. Karki, T. Friščić, W. Jones and W. D. S. Motherwell, *Mol. Pharm.*, 2007, **4**, 347-354.
2. O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. Howard and H. Puschmann, *J. Appl. Crystallogr.*, 2009, **42**, 339-341.
3. G. M. Sheldrick, *Acta Cryst. A*, 2015, **71**, 3-8.
4. G. M. Sheldrick, *Acta Cryst. C*, 2015, **71**, 3-8.
5. (a) M. F. Caso, D. D'Alonzo, S. D'Errico, G. Palumbo and A. Guaragna, *Org. Lett.*, 2015, **17**, 2626-2629; (b) R. Nageswara Rao and K. Santhakumar, *New J. Chem.*, 2016, **40**, 8408-8417.
6. (a) A. Gavezzotti, *Acc. Chem. Res.*, 1994, **27**, 309-314; (b) A. Gavezzotti and G. Filippini, *J. Phys. Chem.*, 1994, **98**, 4831-4837.
7. P. van Roey, W. A. Pangborn, R. F. Schinazi, G. Painter and D. C. Liotta, *Antiviral Chem. Chemother.*, 1993, **4**, 369-375.